MergerBrief Daily: Deal News ARGX/FBRX: argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its
MergerBrief Daily: Deal News ARGX/FBRX: argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline (PR) BCO/NATL: Malaysia Business Accounting Change; Revenue Impact ~$100M (PR) MOBX/PRSO: Nasdaq Minimum Bid Price Deficiency Notice; Annual Meeting Set September 10 (PR) NEE/D: Integration management office formed; regulatory applications filed 7/15 (PR); NEE 10-Q CRH/ACA: Preliminary Proxy; Shareholder Date TBD (Proxy) FHB/TCBK: FHI Q2 2026 net income $73.4M; merger integration planning underway (PR) Long Lake/GBTG: Supplemental Disclosures to Definitive Proxy Statement (PR) BRK-A/TMHC: Berkshire Hathaway Completes Acquisition of Taylor Morrison (PR) Kuva Labs/LSTA: Merger Agreement with Kuva Labs Terminated; Strategic Review Initiated (PR)
MergerBrief Daily: Deal News ARGX/FBRX: argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline (PR) BCO/NATL: Malaysia Business Accounting Change; Revenue Impact ~$100M (PR) MOBX/PRSO: Nasdaq Minimum Bid Price Deficiency Notice; Annual Meeting Set September 10 (PR) NEE/D: Integration management office formed; regulatory applications filed 7/15 (PR); NEE 10-Q CRH/ACA: Preliminary Proxy; Shareholder Date TBD (Proxy) FHB/TCBK: FHI Q2 2026 net income $73.4M; merger integration planning underway (PR) Long Lake/GBTG: Supplemental Disclosures to Definitive Proxy Statement (PR) BRK-A/TMHC: Berkshire Hathaway Completes Acquisition of Taylor Morrison (PR) Kuva Labs/LSTA: Merger Agreement with Kuva Labs Terminated; Strategic Review Initiated (PR)